Targeted therapeutic approaches for hormone-refractory prostate cancer

2010 ◽  
Vol 36 (2) ◽  
pp. 122-130 ◽  
Author(s):  
Flora Stavridi ◽  
Eleni M. Karapanagiotou ◽  
Kostas N. Syrigos
2017 ◽  
Vol 114 (39) ◽  
pp. 10461-10466 ◽  
Author(s):  
Ken-ichi Takayama ◽  
Takashi Suzuki ◽  
Tetsuya Fujimura ◽  
Yuta Yamada ◽  
Satoru Takahashi ◽  
...  

Developing therapeutic approaches are necessary for treating hormone-refractory prostate cancer. Activation of androgen receptor (AR) and its variants’ expression along with the downstream signals are mostly important for disease progression. However, the mechanism for marked increases of AR signals and its expression is still unclear. Here, we revealed that various spliceosome genes are aberrantly induced by RNA-binding protein PSF, leading to enhancement of the splicing activities for AR expression. Our high-speed sequence analyses identified global PSF-binding transcripts. PSF was shown to stabilize and activate key long noncoding RNAs and AR-regulated gene expressions in prostate cancer cells. Interestingly, mRNAs of spliceosome-related genes are putative primary targets of PSF. Their gene expressions are up-regulated by PSF in hormone-refractory prostate cancer. Moreover, PSF coordinated these spliceosome proteins to form a complex to promote AR splicing and expression. Thus, targeting PSF and its related pathways implicates the therapeutic possibility for hormone-refractory prostate cancer.


2007 ◽  
Vol 177 (4S) ◽  
pp. 202-202
Author(s):  
Hirotsugu Uemura ◽  
Motoyoshi Tanaka ◽  
Shigeya Uejima ◽  
Takafumi Minami ◽  
Kiyohide Fujimoto ◽  
...  

2005 ◽  
Vol 173 (4S) ◽  
pp. 225-225
Author(s):  
Peter Olbert ◽  
Andres J. Schrader ◽  
Axel Hegele ◽  
Zoltan Varga ◽  
Axel Heidenreich ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document